Invention Publication
- Patent Title: P63 INACTIVATION FOR THE TREATMENT OF HEART FAILURE
-
Application No.: EP16753173Application Date: 2016-02-19
-
Publication No.: EP3259346A4Publication Date: 2018-07-11
- Inventor: PATEL VIVEKKUMAR B , WANG HONGRAN , SINGH VIVEK P , REINEKE ERIN LYNN , MATHISON MEGUMI , COONEY AUSTIN J , ROSENGART TODD
- Applicant: BAYLOR COLLEGE MEDICINE
- Assignee: BAYLOR COLLEGE MEDICINE
- Current Assignee: BAYLOR COLLEGE MEDICINE
- Priority: US201562118573 2015-02-20
- Main IPC: C12N5/071
- IPC: C12N5/071 ; A61K9/00 ; A61K31/47 ; A61K31/713 ; A61K38/17 ; A61K48/00 ; C07K14/47 ; C07K14/82 ; C12N5/00 ; C12N5/077 ; C12N15/00 ; C12N15/113 ; C12N15/86
Abstract:
Embodiments of the disclosure include methods and compositions for in situ cardiac cell regeneration, including transdifferentiation of cardiac cells to cardiomyocytes. In particular embodiments, in situ cardiac cell regeneration encompasses delivery of p63 shRNA and one or both of Hand2 and myocardin, and in specific embodiments further includes one or more of Gata4, Mef2c, and Tbx5. In specific aspects of the disclosure, adult cardiac fibroblasts are reprogrammed into cardiomyocytes using viral vectors that harbor p63 shRNA and one or both of the transcription factors Hand2 and myocardin.
Information query